Reevaluation of the regulation of beta-adrenergic receptor binding by desipramine treatment

MA Riva and I Creese

Center for Molecular and Behavioral Neuroscience, Rutgers State University of New Jersey, Newark 07102.

Treatment of rats with desipramine (DMI) has been shown to down- regulate beta-adrenergic receptor-stimulated adenylate cyclase and reduce the Bmax of beta-adrenergic receptors in some brain areas. Recent reports have indicated that the down-regulation in the number of beta-adrenergic receptors following DMI treatment does not occur if the serotonin system has been impaired following parachlorophenylalanine (PCPA) or 5,7-dihydroxytryptamine injection. We have previously shown that [3H]dihydroalprenolol ([3H]DHA), the most commonly used radioligand to measure central nervous system beta-adrenergic receptors, labels another site under normal experimental procedures, in addition to the beta-adrenergic receptors. This second site has some pharmacological characteristics of the 5-hydroxytryptamine1A receptor. The depletion of serotonin following PCPA injection was indeed able to prevent the down-regulation of [3H]DHA binding sites after DMI injection. However, PCPA alone increased the density of [3H]DHA binding sites. If the nonlinear, least squares, curve-fitting program LIGAND was allowed to define [3H]DHA nonspecific binding or if the more selective beta-adrenergic receptor radioligand [3H]CGP-1277 was used, the Bmax of beta-adrenergic receptors was not changed after PCPA injection. Importantly, PCPA did not prevent beta-adrenergic receptor down-regulation following DMI treatment. The blockade of 5- hydroxytryptamine2 receptors, via ketanserin administration, during DMI treatment did not change the response of beta-adrenergic receptors. Furthermore, if LIGAND was used to define the nonspecific binding of [3H]DHA, the down-regulation of beta-adrenergic receptors was significant 24 hr after a single DMI injection. The same rapid down- regulation was demonstrated with [3H]CGP-12177. However, if [3H]DHA was used to label beta-adrenergic receptors in the "typical" manner (nonspecific binding defined by 10 microM alprenolol), a decrease in the number of beta-adrenergic receptors was significant only after seven daily DMI injections. These data demonstrate that the use of [3H]DHA to measure beta-adrenergic receptors can be misleading, because changes in its second binding site can conceal the changes occurring in beta-adrenergic receptors. Moreover, these results suggest that a similarity in the time course of action of DMI cannot be used to support the hypothesis that its therapeutic antidepressant action is related to beta-adrenergic receptor down-regulation.

Volume 36, Issue 1, pp. 211-218, 07/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				S. Burgi, K. Baltensperger, and U. E. Honegger Antidepressant-induced Switch of beta 1-Adrenoceptor Trafficking as a Mechanism for Drug Action J. Biol. Chem., January 3, 2003; 278(2): 1044 - 1052. [Abstract] [Full Text] [PDF]

				M. J. Millan, A. Newman-Tancredi, J.-M. Rivet, M. Brocco, P. Lacroix, V. Audinot, L. Cistarelli, and A. Gobert S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: I. Interaction with Cloned Human (h)5-HT1A, Dopamine hD2/hD3 and halpha 2A-Adrenergic Receptors in Relation to Modulation of Cortical Monoamine Release and Activity in Models of Potential Antidepressant Activity J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 132 - 147. [Abstract] [Full Text]